{"id":112498,"title":"Hemogenyx Pharma Plc (LON:HEMO) Approval and Issuance of U.S. Conditioning Patent","publisher":"Share Talk","author":"sharetalk","published":"2024-02-02T08:28:50+00:00","modified":"2024-02-02T08:28:50+00:00","canonical_url":"https://www.share-talk.com/hemogenyx-pharma-plc-lonhemo-approval-and-issuance-of-u-s-conditioning-patent/","markdown_url":"https://www.share-talk.com/hemogenyx-pharma-plc-lonhemo-approval-and-issuance-of-u-s-conditioning-patent.md","json_url":"https://www.share-talk.com/hemogenyx-pharma-plc-lonhemo-approval-and-issuance-of-u-s-conditioning-patent.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["biopharmaceutica","COVID-19","Dr Vladislav Sandler","Global Pharma","gold rush","H.C. Wainwright","HEMO","Hemogenyx","Hemogenyx Pharma","Pharma","Share Talk","Vladislav Sandler"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Hemogenyx-Pharma-27_11_23.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"**HemoGenyx Pharmaceuticals (LON: HEMO)** announced the approval of a crucial patent application by the United States Patent and Trademark Office, safeguarding its innovative CDX antibody technology.\n\nThe granted patent, titled ‘Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodies’, marks a significant milestone in the company’s intellectual property portfolio.\n\nVladislav Sandler, the Chief Executive Officer, commented, “The approval of this patent is a major enhancement to our intellectual property rights surrounding CDX, which continues to be a pivotal product candidate for our future endeavours. This achievement further establishes our firm’s leadership in the field of conditioning for bone marrow transplants.”\n\n**About Hemogenyx Pharmaceuticals plc**\n\nHemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.\n\nThe Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development."}